TRCT
PRLD icon

Tower Research Capital (TRC)’s Prelude Therapeutics PRLD Stock Holding History

Tower Research Capital (TRC)’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,927
Closed -$9.97K – 5485
2025
Q3 		$9.97K Sell
6,927
-9,872
-59% -$9.89K ﹤0.01% 4007
2025
Q2 		$13.6K Buy
16,799
+3,213
+24% +$2.78K ﹤0.01% 3858
2025
Q1 		$10.4K Buy
13,586
+3,210
+31% +$2.99K ﹤0.01% 3637
2024
Q4 		$13.2K Buy
10,376
+5,074
+96% +$6.73K ﹤0.01% 3548
2024
Q3 		$11K Sell
5,302
-1,762
-25% -$8.16K ﹤0.01% 3705
2024
Q2 		$26.9K Buy
7,064
+3,717
+111% +$15.1K ﹤0.01% 3567
2024
Q1 		$15.9K Sell
3,347
-645
-16% -$2.51K ﹤0.01% 3218
2023
Q4 		$17K Buy
3,992
+492
+14% +$1.5K ﹤0.01% 3751
2023
Q3 		$10.8K Buy
3,500
+1,410
+67% +$5.29K ﹤0.01% 4075
2023
Q2 		$9.4K Sell
2,090
-11,262
-84% -$67.3K ﹤0.01% 4290
2023
Q1 		$76K Buy
13,352
+9,820
+278% +$59.9K ﹤0.01% 2120
2022
Q4 		$21K Buy
3,532
+2,278
+182% +$14.6K ﹤0.01% 3099
2022
Q3 		$9K Sell
1,254
-2,770
-69% -$18.7K ﹤0.01% 4678
2022
Q2 		$21K Buy
4,024
+1,689
+72% +$8.6K ﹤0.01% 3752
2022
Q1 		$16K Sell
2,335
-2,985
-56% -$27.3K ﹤0.01% 3766
2021
Q4 		$66K Buy
5,320
+1,821
+52% +$29.6K ﹤0.01% 2543
2021
Q3 		$109K Buy
3,499
+2,434
+229% +$78.8K ﹤0.01% 2332
2021
Q2 		$31K Sell
1,065
-1,740
-62% -$62K ﹤0.01% 3458
2021
Q1 		$122K Buy
2,805
+2,600
+1,268% +$172K ﹤0.01% 2436
2020
Q4 		$15K Buy
+205
New +$10.2K ﹤0.01% 4053

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s PRLD Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Prelude Therapeutics (PRLD) in Q4 2025, closing a stake of 6,927 shares — an estimated $9.97K sold.

Tower Research Capital (TRC) first reported a position in PRLD in Q4 2020 and held it in 20 quarters. The position peaked at $122K in Q1 2021. 48 funds tracked by Wall St. Rank hold PRLD as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Prelude Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 6,927 Prelude Therapeutics shares in Q4 2025, an estimated $9.97K.
  • Tower Research Capital (TRC) first reported a position in Prelude Therapeutics in Q4 2020 and held it in 20 quarters.
  • Tower Research Capital (TRC)'s Prelude Therapeutics position peaked at $122K in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.